Trial reportScientific reports2025
Efficacy analysis of TACE in combination with anlotinib and sintilimab in the treatment of unresectable hepatocellular carcinoma.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of PD-1/PD-L1 inhibitors combined with anti-VEGF/TKIs and TACE in uHCC: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To investigate the effectiveness of TACE in combination with anlotinib and sintilimab in the treatment of unresectable hepatocellular carcinoma. A total of 210 patients with primary unresectable hepatocellular carcinoma (PAC) in our hospital from January 2020 to December 2023 were selected as the study subjects, and they were divided into two groups of 105 cases each by the envelope method using sequentially numbered, opaque sealed envelopes containing computer-generated random allocations. The control group was treated with TACE combined with anlotinib, and the study group was treated with sintilimab on the basis of the control group, and all patients were followed up for 18 months or until death or loss to follow-up, and the differences in treatment efficacy, safety, tumor markers, tumor growth factors and patient recovery between the two groups were compared. The DCR and ORR of the study group were 81.90% and 49.52%, which were significantly higher than those of the control group (61.90%) and 35.24%, and the difference was statistically significant(P = 0.042 and P = 0.029, respectively). The PFS (12.54 ± 0.39 months) and OS (17.52 ± 0.98 months) in the study group were significantly higher than those in the control group (8.65 ± 0.97 months) and OS (12.94 ± 1.55 months), and the difference was statistically significant (P = 0.001), and the survival rates of patients in the study group were 75.24% and 53.33% after 12 months and 18 months, which were significantly higher than those in the control group (70.48% and 31.43%), and the difference was statistically significant(P = 0.013 and P = 0.011, respectively). The incidence of myelosuppression and liver damage in grade 1 ~ 3 adverse reactions in the study group was significantly higher than that in the control group, and the difference was statistically significant(P = 0.035 and P = 0.021, respectively). No patient experienced grade 4–5 adverse reactions. There was no significant difference in the scores of CEA, AFP, CD3+, CD4+, CD4+/CD8+, NK cells, VEGF, PDGF, KPS and QLQ-C30 between the two groups before treatment (P > 0.05), and the KPS scores were significantly higher than those before treatment, and the levels of VEGF, PDGF, CEA, AFP, CD3+, CD4+, CD4+/CD8+, NK cells and QLQ-C30 were significantly lower than those before treatment. The difference was statistically significant (P < 0.001), the CD3+, CD4+, CD4+/CD8+, NK cell levels and KPS scores in the study group were significantly higher than those in the control group, and the scores of VEGF, PDGF, CEA, AFP and QLQ-C30 were significantly lower than those in the control group, and the difference was statistically significant (P < 0.001). The treatment of TACE combined with anlotinib and sintilimab in patients with intermediate-stage unresectable hepatocellular carcinoma can effectively improve the short-term and long-term treatment efficacy, and adverse reactions can be tolerated by patients, and can effectively reduce the level of tumor markers, reduce tumor angiogenesis, improve patients’ immune function, and improve the survival rate of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.